Stoke Therapeutics Inc Stock
Stoke Therapeutics Inc Stock
A loss of -1.670% shows a downward development for Stoke Therapeutics Inc.
We see a rather positive sentiment for Stoke Therapeutics Inc with 15 Buy predictions and 1 Sell predictions.
As a result the target price of 21 € shows a very positive potential of 82.61% compared to the current price of 11.5 € for Stoke Therapeutics Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Stoke Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Stoke Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stoke Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | -1.670% | -3.361% | - | - | - | - | - |
| Personalis Inc | 5.820% | -9.049% | -19.044% | -57.461% | -42.981% | -93.921% | - |
| Immuron | -5.740% | -2.400% | 2.521% | 48.780% | 46.108% | -46.256% | - |
Comments
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Wedbush from $13.00 to $17.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat